Health Care • Biotechnology: Pharmaceutical Preparations
$48.75 ▲ +0.96
(+2.01%)
MKT CAP: $2.31B • VOL: 343.4K
52W L $43 52W H $71
PBH // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-03-31 | FY 2024
FILED 2025-03-31 | FY 2023
FILED 2024-03-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.09B | $1.14B | $1.13B |
| YoY Revenue Growth % | -4.3% | +1.1% | — |
| Gross Profit | $595.6M | $634.5M | — |
| Gross Margin % | 54.7% | 55.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $309.4M | $336.8M | $342.4M |
| Operating Margin % | 28.4% | 29.6% | 30.4% |
| Net Income (GAAP) | $190.3M | $214.6M | $209.3M |
| EBITDA (Normalized) | $318.4M | $343.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $257.6M | $251.5M | $248.9M |
| Capital Expenditures (CapEx) | $11.2M | $8.2M | — |
| Free Cash Flow (FCF) | $246.4M | $243.3M | $248.9M |
| FCF Margin % | 22.6% | 21.4% | 22.1% |
| Return on Invested Capital (ROIC %) | 13.8% | 9.7% | — |
| Cash & Short-Term Equivalents | $62.4M | $50.9M | — |
| Total Debt (Short + Long Term) | — | $1.00B | — |
| Total Stockholders' Equity | $1.83B | $1.79B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PBH.